Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SENTI-202 by Senti Biosciences for Myelodysplastic Syndrome: Likelihood of Approval
SENTI-202 is under clinical development by Senti Biosciences and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
SENTI-202 by Senti Biosciences for Refractory Acute Myeloid Leukemia: Likelihood of Approval
SENTI-202 is under clinical development by Senti Biosciences and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
SENTI-202 by Senti Biosciences for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
SENTI-202 is under clinical development by Senti Biosciences and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...